ANGO

Angiodynamics

• NASDAQ·2d ago

  Freedom Broker Initiates Coverage of AngioDynamics (ANGO) with Buy Recommendation

• Dow Jones·2d ago

  AngioDynamics Initiated at Buy by Freedom Broker

• Dow Jones·3d ago

  AngioDynamics Is Maintained at Buy by Canaccord Genuity

• Dow Jones·3d ago

  AngioDynamics Price Target Cut to $16.00/Share From $18.00 by Canaccord Genuity

• Benzinga·3d ago

  Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $16

• TipRanks·3d ago

  AngioDynamics initiated with a Buy at Freedom Broker

• TipRanks·3d ago

  AngioDynamics: Improving Fundamentals and Strategic Transition Support Buy Rating and Higher Price Target

• TipRanks·4d ago

  AngioDynamics price target lowered to $16 from $18 at Canaccord

• TipRanks·4d ago

  Canaccord Genuity Remains a Buy on AngioDynamics (ANGO)

• TipRanks·4d ago

  AngioDynamics Earnings Call Highlights Med Tech Momentum

• Seeking Alpha·5d ago

  AngioDynamics Growing, But With More Noise Than The Street Likes

• Simply Wall St·04/03 01:47

  AngioDynamics (ANGO) Margins Stay Negative In Q2 2026 And Test Bullish Turnaround Hopes

• TipRanks·04/02 16:29

  Midday Fly By: Amazon said to eye Globalstar, Tesla deliveries miss consensus

• Seeking Alpha·04/02 14:13

  AngioDynamics signals FY2026 adjusted EBITDA of $10M-$12M while raising net sales guidance to $313.5M-$315.5M

• TipRanks·04/02 12:12

  AngioDynamics Posts Strong Q3 Results, Raises 2026 Guidance